Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement
Meta-analysis published in Cochrane Database Syst Rev (2010)
Abstract
BACKGROUND: Patients who have undergone total hip or knee replacement (THR, TKR) have a high risk of developing venous thromboembolism (VTE) following surgery, despite appropriate anticoagulation with warfarin or low molecular weight heparin (LMWH). New anticoagulants are under investigation. OBJECTIVES: To examine the efficacy and safety of prophylactic anticoagulation with direct thrombin inhibitors (DTIs) versus LMWH or vitamin K antagonists in the prevention of VTE in patients undergoing THR or TKR. SEARCH STRATEGY: The Cochrane Peripheral Vascular Disease Group searched their Specialized Register (last searched 12 March 2010) and CENTRAL (last searched 2010, Issue 2). SELECTION CRITERIA: Randomised controlled trials. DATA COLLECTION AND ANALYSIS: Three reviewers independently assessed methodological quality and extracted data in pre-designed tables. The reported follow-up events were included MAIN RESULTS: We included 14 studies included involving 21,642 patients evaluated for efficacy and 27,360 for safety. No difference was observed in major VTE in DTIs compared with LMWH in both types of operations (odds ratio (OR) 0.91; 95% confidence interval (CI) 0.69 to 1.19), with high heterogeneity (I(2) 71%). No difference was observed with warfarin (OR 0.85; 95% CI 0.63 to 1.15) in TKR, with no heterogeneity (I(2) 0%).More total bleeding events were observed in the DTI group (in ximelagatran and dabigatran but not in desirudin) in patients subjected to THR (OR 1.40; 95% CI 1.06, 1.85; I(2) 41%) compared with LMWH. No difference was observed with warfarin in TKR (OR 1.76; 95% CI 0.91 to 3.38; I(2) 0%). All-cause mortality was higher in the DTI group when the reported follow-up events were included (OR 2.06; 95% CI 1.10 to 3.87).Studies that initiated anticoagulation before surgery showed less VTE events; those that began anticoagulation after surgery showed more VTE events in comparison with LMWH. Therefore, the effect of the DTIs compared with LMWH appears to be influenced by the time of initiation of coagulation more than the effect of the drug itself.The results obtained from sensitivity analysis, did not differ from the analysed results; this strengthens the value of the results. AUTHORS' CONCLUSIONS: Direct thrombin inhibitors are as effective in the prevention of major venous thromboembolism in THR or TKR as LMWH and vitamin K antagonists. However, they show higher mortality and cause more bleeding than LMWH. No severe hepatic complications were reported in the analysed studies. Use of ximelagatran is not recommended for VTE prevention in patients who have undergone orthopedic surgery. More studies are necessary regarding dabigatran.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Patients who have undergone total hip or knee replacement (THR, TKR) have a high risk of developing venous thromboembolism (VTE) following surgery, despite appropriate anticoagulation with warfarin or low molecular weight heparin (LMWH).
Warum dies für die Hirudotherapie relevant ist
Dieser Cochrane-Review von 14 randomisierten Studien (21.642 Patienten für die Wirksamkeit ausgewertet; 27.360 für die Sicherheit) untersuchte direkte Thrombininhibitoren versus NMH oder Warfarin zur VTE-Prophylaxe nach totaler Hüft- oder Knieendoprothese und fand eine vergleichbare Wirksamkeit, jedoch eine höhere Gesamtmortalität und mehr Gesamtblutungen unter DTIs – wobei Desirudin im Vergleich zu NMH allerdings keinen Blutungsüberschuss zeigte. Für ASH ist dies unmittelbar relevant, da Desirudin rekombinantes Hirudin ist, das charakteristische Antikoagulans des Speichels medizinischer Blutegel und ein Produkt des pharmakologischen Erbes der Hirudotherapie; die Beobachtung, dass sich das Blutungsprofil von Desirudin vorteilhaft von dem anderer DTIs unterschied, liefert klinisch bedeutsame Sicherheitsdaten zu einem aus dem Blutegelsekretom stammenden Therapeutikum. Eine wesentliche Einschränkung: Der Review poolte heterogene DTIs unterschiedlicher molekularer Herkunft und Nachbeobachtungsdauern, und seine Ergebnisse betreffen die kurzfristige chirurgische Prophylaxe und nicht die breiteren klinischen Kontexte, in denen die Blutegeltherapie selbst zur Anwendung kommt.
Zitation
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Salazar CA et al. · Cochrane Database Syst Rev, 2010
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026